Events Partner Content 4th RAS-Targeted Drug Development Summit For decades, RAS has existed as an elusive therapeutic target, and drugging this high-value oncogene was deemed impossible.
News Aldeyra’s reproxalap for dry eye disease accepted by FDA Biotech Aldeyra Therapeutics has announced that the US Food and Drug Administration (FDA) has accepted its New D
News Welcome to the new pharmaphorum Our website has served us well over the years, but after five years since the last re-design – during which aesthetic standards have changed and website technology has improved